A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult

PHASE1RecruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

March 23, 2024

Primary Completion Date

January 6, 2025

Study Completion Date

December 6, 2025

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

GR2102 injection

single dose

BIOLOGICAL

placebo

single dose

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY